CN105517562B - 转移抑制剂 - Google Patents

转移抑制剂 Download PDF

Info

Publication number
CN105517562B
CN105517562B CN201480031461.3A CN201480031461A CN105517562B CN 105517562 B CN105517562 B CN 105517562B CN 201480031461 A CN201480031461 A CN 201480031461A CN 105517562 B CN105517562 B CN 105517562B
Authority
CN
China
Prior art keywords
peptide
seq
cancer
cell
mans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480031461.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN105517562A (zh
Inventor
I·帕里克
K·B·阿德勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
Biomarck Pharmaceuticals Ltd
Original Assignee
North Carolina State University
Biomarck Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University, Biomarck Pharmaceuticals Ltd filed Critical North Carolina State University
Publication of CN105517562A publication Critical patent/CN105517562A/zh
Application granted granted Critical
Publication of CN105517562B publication Critical patent/CN105517562B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Virology (AREA)
CN201480031461.3A 2013-04-05 2014-04-07 转移抑制剂 Expired - Fee Related CN105517562B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361808966P 2013-04-05 2013-04-05
US61/808,966 2013-04-05
PCT/US2014/033206 WO2014165853A1 (en) 2013-04-05 2014-04-07 Inhibitors of metastasis

Publications (2)

Publication Number Publication Date
CN105517562A CN105517562A (zh) 2016-04-20
CN105517562B true CN105517562B (zh) 2018-12-28

Family

ID=51654619

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480031461.3A Expired - Fee Related CN105517562B (zh) 2013-04-05 2014-04-07 转移抑制剂

Country Status (19)

Country Link
US (4) US9408886B2 (enExample)
EP (1) EP2981279B1 (enExample)
JP (1) JP6449849B2 (enExample)
KR (1) KR102191695B1 (enExample)
CN (1) CN105517562B (enExample)
AU (1) AU2014247979B2 (enExample)
BR (1) BR112015025398A2 (enExample)
CA (1) CA2908832C (enExample)
DK (1) DK2981279T3 (enExample)
ES (1) ES2714863T3 (enExample)
HU (1) HUE043971T2 (enExample)
IL (1) IL241937B (enExample)
MX (1) MX363077B (enExample)
PL (1) PL2981279T3 (enExample)
PT (1) PT2981279T (enExample)
RU (1) RU2681213C2 (enExample)
SG (2) SG10201708125PA (enExample)
WO (1) WO2014165853A1 (enExample)
ZA (1) ZA201508010B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105517562B (zh) * 2013-04-05 2018-12-28 拜欧马可医药公司 转移抑制剂
CN108686220A (zh) * 2018-07-13 2018-10-23 刘慧荣 一种针对甲状腺癌的抗肿瘤剂
EP4475866A4 (en) * 2022-02-07 2026-02-25 Park Strategic Ventures Llc Peptides and their methods of use in the treatment of eye disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1564696A (zh) * 2001-10-05 2005-01-12 宾西法尼亚大学托管人 治疗和预防全身炎性反应综合症/败血症的药物组成和方法
CN101516190A (zh) * 2006-07-26 2009-08-26 拜欧马克医药有限公司 减少炎症介质释放的方法和可用于该方法的肽

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
WO2003000027A2 (en) 2001-06-26 2003-01-03 North Carolina State University Blocking peptide for inflammatory cell secretion
DE60308251T2 (de) 2002-04-17 2007-08-30 Canon K.K. Vorrichtung zur Bereitstellung von öffentlichen Schlüsselzertifikaten
WO2006078899A2 (en) 2005-01-20 2006-07-27 Biomarck Pharmaceuticals, Ltd. Mucin hypersecretion inhibitors based on the structure of mans and methods of use
WO2006086681A2 (en) * 2005-02-09 2006-08-17 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting smooth muscle cell migration and proliferation
EP2069477A4 (en) * 2006-10-06 2010-12-08 Celtaxsys Inc Chemorepulsion of cells
JP2010508512A (ja) 2006-10-27 2010-03-18 ジョージ メイソン インテレクチュアル プロパティーズ，インコーポレイテッド オブ フェアファックス，バージニア 転移性結腸直腸癌のアッセイ
WO2009062128A2 (en) * 2007-11-08 2009-05-14 Indiana University Research And Technology Corporation Combination drug therapy for the treatment of cancer
EP2105511A1 (en) * 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
US9073974B2 (en) 2009-12-21 2015-07-07 The Regents Of The University Of California RGD-containing cyclic peptides
EP3351641A1 (en) * 2011-04-08 2018-07-25 Tufts Medical Center, Inc. Pepducin design and use
CN105517562B (zh) * 2013-04-05 2018-12-28 拜欧马可医药公司 转移抑制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1564696A (zh) * 2001-10-05 2005-01-12 宾西法尼亚大学托管人 治疗和预防全身炎性反应综合症/败血症的药物组成和方法
CN101516190A (zh) * 2006-07-26 2009-08-26 拜欧马克医药有限公司 减少炎症介质释放的方法和可用于该方法的肽

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Myristoylated Alanine-Rich protein Kinase C Substrate (MARCKS) expression modulates the metastatic phenotype in human and murine colon carcinoma in vitro and in vivo;Krista Rombouts et al;《Cancer Letters》;20130129;第333卷(第2期);摘要，材料与方法部分，第3.1、3.2、3.5、3.7节，第249页讨论部分，第251页讨论部分，图7 *

Also Published As

Publication number Publication date
IL241937B (en) 2019-03-31
PT2981279T (pt) 2019-03-14
WO2014165853A1 (en) 2014-10-09
EP2981279A1 (en) 2016-02-10
CA2908832C (en) 2023-01-24
RU2015146997A (ru) 2017-05-15
ZA201508010B (en) 2017-01-25
RU2681213C2 (ru) 2019-03-05
US9408886B2 (en) 2016-08-09
JP2016516756A (ja) 2016-06-09
NZ712955A (en) 2021-03-26
SG10201708125PA (en) 2017-11-29
DK2981279T3 (en) 2019-03-25
KR102191695B1 (ko) 2020-12-16
US10683328B2 (en) 2020-06-16
JP6449849B2 (ja) 2019-01-09
US20190119320A1 (en) 2019-04-25
EP2981279B1 (en) 2018-12-19
HUE043971T2 (hu) 2019-09-30
CA2908832A1 (en) 2014-10-09
US20210130403A1 (en) 2021-05-06
CN105517562A (zh) 2016-04-20
AU2014247979B2 (en) 2018-06-28
EP2981279A4 (en) 2016-11-09
MX363077B (es) 2019-03-07
MX2015014036A (es) 2016-02-25
HK1221159A1 (en) 2017-05-26
US20170121369A1 (en) 2017-05-04
BR112015025398A2 (pt) 2017-10-10
US11466054B2 (en) 2022-10-11
US20140302057A1 (en) 2014-10-09
RU2015146997A3 (enExample) 2018-03-13
US10011636B2 (en) 2018-07-03
KR20150140736A (ko) 2015-12-16
SG11201508249WA (en) 2015-11-27
PL2981279T3 (pl) 2019-09-30
ES2714863T3 (es) 2019-05-30
AU2014247979A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
US11466273B2 (en) Monocarboxylate transporter 4 (MCT4) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer
CN109069528A (zh) 通过DBait分子的全身性给药治疗癌症
US11466054B2 (en) Inhibitors of metastasis
AU2019343965B2 (en) Targeting moiety-drug grafted immune cell compositions and methods of use
CN110062633A (zh) 酪氨酸衍生物以及包含所述酪氨酸衍生物的组合物
US20250319172A1 (en) Anticancer vaccine composition comprising hsp90 antigenic peptide and use thereof
EP3323411A1 (en) Composition for inhibiting angiogenesis containing nanoparticle-vitreous body-based protein complex as active ingredient, and use thereof
WO2016071431A9 (en) A combination for cancer therapy
US20250339539A1 (en) Phosphate Membrane Nanodiscs Conjugated to Therapeutic Agents and Medical Uses Thereof
CN108348539A (zh) 用于治疗肿瘤的方法
JP2009509974A (ja) 抗癌治療

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181228